… government scrutiny for its high drug costs. One factor likely keeping … Hodgkin lymphoma treatment Matulane by 15%. In addition, Collegium Pharmaceuticals increased the … at 42% and Bayer’s Nexavar at 50%.

… to essential medicines and the broader pharmaceutical industry. Product … for the kidney cancer drug Nexavar. Even during the Covid … urgent access to critical drugs was paramount, the government … authorising local manufacturing of patented drugs — can be a …

… $1 billion in annualized gross Medicaid expenditures. Additionally, the report mentions … ; Duchesnay), and sofafenib (Nexavar; Bayer). For all the drugs with decreases, the … . HHS Announces Next 15 Drugs for Medicare Part D Price Negotiations. Pharmacy …

… (EMA)’s Committee for Medicinal Products for Human Use … phase 3 CheckMate 9DW trial (NCT04039607), which assessed nivolumab … (Lenvima) or sorafenib (Nexavar) in patients who were … and Drug Administration sBLA acceptance for first-line treatment of …

… generic version of the drug product(s), if there … may contribute to wrong drug errors FDA is evaluating the … ), co-packaged Drug-induced liver injury FDA is evaluating the … lenvatinib) capsules Nexavar (sorafenib) tablets Tumor lysis syndrome FDA is evaluating …

… hospitals, clinics, medical services, and pharmaceutical companies is a … up with top Indian doctors remotely, offering affordable, … drug Nexavar, significantly lowering treatment costs. Partnerships with international medical device and pharmaceutical …

… in developing effective treatments for patients with … ponatinib (Iclusig), sorafenib (Nexavar), ceritinib (Zykadia), and homoharringtonine … trial right now, the FDA-approved phase 1 trial … al. Identification of pharmaceutics with selective activity against …

… Nexavar® (Bayer Pharmaceuticals), as a first-line chemotherapeutic agent for the treatment … are sophisticated herbal remedies that are formed … II clinical trials committee, hepatic drug targeting: phase … nano-medicine. Artif Cells Nanomed Biotechnol. 2018 …

… of Medicine Harvard Medical School Boston, MA Targeted Oncology: What treatments … 1 recommendation, and sorafenib [Nexavar] is included as another … evidence in the SELECT trial [NCT01321554]. There are alternatives … to receive the study drug. To detect an OS …

… the drug is costly to manufacture, or if the pharmaceutical company … a key hepatitis C treatment was priced at Rs 70 … Thailand by withdrawing new medicines from the country, including … granted 2012 compulsory license on Nexavar (sorafenib), Marijn Dekkers, …